"From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher. The past couple of years have been a transformative time for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines and GLP-1 drugs, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities. Meanwhile, it has struggled to meet overwhelming demand and faces intense competition in the weight-loss space."
"Now, the share price is 34.1% higher than six months ago, despite a 6% retreat in the past few trading days. In the past month, Lilly acquired Ventyx Biosciences for $1.2 billion, announced positive clinical results, and slashed prices for Mounjaro and Zepbound in China to be more competitive. Also, Lilly became the first healthcare company to reach a $1 trillion market capitalization."
From late 2020 through summer 2024, Eli Lilly's stock climbed more than 635% driven by GLP-1 drugs, innovative medicines, regulatory successes, and increased pipeline and manufacturing investment. Revenue since 2016 rose significantly while net income grew even faster. The company has struggled to meet overwhelming demand and faces intense competition in the weight‑loss market. Recent actions include acquiring Ventyx Biosciences for $1.2 billion, announcing positive clinical results, and cutting prices for Mounjaro and Zepbound in China. The share price is 34.1% above its six‑month level despite a recent 6% pullback, and future forecasts model scenarios through 2025–2030.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]